Vivos Therapeutics (VVOS) Q2 2024 earnings summary

Executive summary

• Revenue increased 19% year-over-year and sequentially in Q2 2024 to $4.1 million, driven by higher product and service sales, improved pricing, and reduced discounts.

• Operating loss decreased 57% year-over-year to $1.9 million, and net loss narrowed to $1.9 million from $5.5 million in Q2 2023, reflecting cost reductions and improved gross profit.

• Gross margin improved to 65% from 62% in Q2 2023, reflecting better pricing discipline and cost controls.

• Cash and cash equivalents rose to $6.9 million as of June 30, 2024, following a $7.5 million equity investment, supporting a strategic shift to alliance-based distribution.

• The company is focused on expanding its provider network, launching new alliances, and expects future growth and profitability from its medical-based sleep center strategy.

Financial highlights

• Q2 2024 revenue was $4.1 million, up from $3.4 million in Q2 2023; six-month revenue reached $7.5 million.

• Gross profit for Q2 2024 was $2.7 million (65% margin), up from $2.1 million in Q2 2023.

• Operating expenses for Q2 2024 were $4.6 million, down from $6.6 million in Q2 2023.

• Net loss for Q2 2024 was $1.9 million, improved from $5.5 million in Q2 2023; net loss per share improved to $0.60 from $4.62.

• Cash and cash equivalents as of June 30, 2024, were $6.9 million; stockholders' equity was $6.3 million, meeting Nasdaq requirements.

Outlook and guidance

• Management anticipates positive cash flow in early 2025, supported by cost reductions and new strategic alliances.

• The new alliance-based model is expected to increase patient volume, drive revenue, and lower acquisition costs.

• Full impact of the Colorado alliance is expected in Q4 2024, with plans for nationwide expansion.

• Additional equity financing may be required to sustain operations and maintain Nasdaq compliance.

• There is substantial doubt about the ability to continue as a going concern without further funding.